Index -
P/E -
EPS (ttm) -0.93
Insider Own 8.07%
Shs Outstand 44.68M
Perf Week -6.44%
Market Cap 181.85M
Forward P/E -
EPS next Y -1.05
Insider Trans 0.84%
Shs Float 41.07M
Perf Month -29.22%
Income -41.47M
PEG -
EPS next Q -0.25
Inst Own 12.70%
Short Float 9.71%
Perf Quarter 173.15%
Sales 0.49M
P/S 371.12
EPS this Y -4.78%
Inst Trans -10.89%
Short Ratio 2.16
Perf Half Y 299.02%
Book/sh 1.56
P/B 2.61
EPS next Y -8.26%
ROA -41.90%
Short Interest 3.99M
Perf Year 164.29%
Cash/sh 1.67
P/C 2.43
EPS next 5Y -
ROE -47.07%
52W Range 0.94 - 6.42
Perf YTD 175.00%
Dividend Est. -
P/FCF -
EPS past 5Y 35.42%
ROI -58.24%
52W High -36.60%
Beta 2.03
Dividend TTM -
Quick Ratio 7.41
Sales past 5Y 9.26%
Gross Margin 18.44%
52W Low 332.98%
ATR (14) 0.48
Dividend Ex-Date -
Current Ratio 7.41
EPS Y/Y TTM -4.47%
Oper. Margin -9305.74%
RSI (14) 38.62
Volatility 6.33% 9.96%
Employees 32
Debt/Eq 0.03
Sales Y/Y TTM 26.42%
Profit Margin -8496.93%
Recom 1.00
Target Price 10.50
Option/Short Yes / Yes
LT Debt/Eq 0.02
EPS Q/Q -7.34%
Payout -
Rel Volume 0.28
Prev Close 3.99
Sales Surprise 212.00%
EPS Surprise 21.38%
Sales Q/Q 21.87%
Earnings May 02 AMC
Avg Volume 1.84M
Price 4.07
SMA20 -20.02%
SMA50 -3.00%
SMA200 88.26%
Trades
Volume 515,037
Change 2.01%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-05-22 Initiated
William Blair
Outperform
Dec-08-21 Initiated
Robert W. Baird
Outperform
$19
Aug-09-21 Resumed
Maxim Group
Buy
$30 → $20
Oct-22-20 Initiated
H.C. Wainwright
Buy
$27
Oct-08-20 Initiated
Piper Sandler
Overweight
$25
Apr-25-24 04:05PM
Apr-08-24 04:05PM
Apr-01-24 08:50AM
Mar-21-24 07:55AM
Mar-14-24 08:50AM
08:08AM
Loading…
08:08AM
Mar-06-24 04:05PM
12:00PM
Mar-01-24 10:12AM
Feb-29-24 07:40PM
04:07PM
04:06PM
04:05PM
Feb-26-24 08:00AM
Feb-22-24 08:00AM
10:30AM
Loading…
Jan-17-24 10:30AM
Nov-20-23 04:05PM
Nov-02-23 04:05PM
Oct-26-23 04:05PM
Oct-23-23 08:45AM
Oct-11-23 09:35AM
Sep-26-23 04:05PM
Sep-05-23 08:00AM
Aug-09-23 04:05PM
Aug-07-23 04:05PM
Jul-24-23 05:09PM
Jun-20-23 05:22PM
Jun-05-23 08:00AM
May-04-23 04:10PM
Mar-28-23 08:00AM
08:15AM
Loading…
Mar-06-23 08:15AM
Mar-04-23 07:11AM
Mar-02-23 04:10PM
Feb-27-23 08:15AM
Feb-02-23 08:00AM
Jan-10-23 08:00AM
Nov-21-22 10:52AM
Nov-08-22 08:15AM
Nov-03-22 04:10PM
Sep-12-22 04:05PM
Sep-10-22 07:30AM
Sep-08-22 08:15AM
Sep-06-22 08:00AM
Aug-29-22 08:00AM
Aug-04-22 04:10PM
Jul-05-22 08:30AM
Jul-02-22 09:10AM
May-17-22 08:30AM
May-09-22 08:02AM
May-05-22 04:10PM
Apr-12-22 04:00PM
Apr-08-22 01:05PM
01:05PM
Mar-22-22 09:05AM
Mar-17-22 06:32AM
Mar-08-22 04:45PM
Mar-01-22 08:30AM
Feb-24-22 04:10PM
Feb-17-22 03:02PM
Jan-31-22 06:22PM
Jan-20-22 03:44PM
01:46PM
Jan-18-22 05:00PM
Jan-13-22 09:17AM
Jan-11-22 08:00AM
Jan-10-22 08:00AM
Jan-04-22 08:00AM
Dec-28-21 09:38AM
Dec-21-21 09:38AM
Dec-16-21 09:38AM
Dec-10-21 08:30AM
Dec-08-21 09:38AM
Dec-03-21 08:30AM
Nov-18-21 07:00AM
Nov-14-21 07:18AM
Nov-09-21 08:30AM
Nov-04-21 04:15PM
Oct-28-21 03:06PM
Sep-30-21 08:36PM
Sep-15-21 06:37AM
Sep-08-21 04:00PM
Sep-07-21 08:30AM
Aug-25-21 08:15AM
Aug-06-21 04:15AM
(Simply Wall St.) +11.84%
Aug-05-21 04:15PM
Aug-03-21 03:01PM
Jul-12-21 08:00AM
Jul-06-21 08:30AM
Jun-28-21 08:30AM
Jun-10-21 12:30PM
Jun-08-21 08:30AM
May-24-21 08:35AM
02:09AM
May-20-21 08:30AM
May-06-21 04:10PM
Apr-23-21 11:39AM
Apr-12-21 06:00AM
Apr-10-21 08:30AM
08:30AM
Apr-08-21 08:30AM
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
PACE GARY W Director Dec 19 '23 Buy 1.37 30,000 41,100 697,761 Dec 19 06:39 PM
Index -
P/E -
EPS (ttm) -12.97
Insider Own 25.72%
Shs Outstand 1.17M
Perf Week -15.76%
Market Cap 3.63M
Forward P/E -
EPS next Y -
Insider Trans 0.00%
Shs Float 0.87M
Perf Month -17.77%
Income -15.19M
PEG -
EPS next Q -
Inst Own 3.26%
Short Float 1.71%
Perf Quarter -0.03%
Sales 0.00M
P/S -
EPS this Y -
Inst Trans -18.04%
Short Ratio 0.60
Perf Half Y -57.82%
Book/sh 1.65
P/B 1.88
EPS next Y -
ROA -103.68%
Short Interest 0.01M
Perf Year -53.55%
Cash/sh 7.81
P/C 0.40
EPS next 5Y -
ROE -164.09%
52W Range 2.40 - 11.77
Perf YTD -3.16%
Dividend Est. -
P/FCF -
EPS past 5Y -20.69%
ROI -785.26%
52W High -73.67%
Beta 1.52
Dividend TTM -
Quick Ratio 1.25
Sales past 5Y 0.00%
Gross Margin -
52W Low 29.06%
ATR (14) 0.38
Dividend Ex-Date -
Current Ratio 1.25
EPS Y/Y TTM 29.85%
Oper. Margin 0.00%
RSI (14) 40.73
Volatility 9.29% 8.49%
Employees 7
Debt/Eq 0.00
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 20.00
Option/Short No / Yes
LT Debt/Eq 0.00
EPS Q/Q -52.74%
Payout -
Rel Volume 0.21
Prev Close 2.92
Sales Surprise -
EPS Surprise -29.00%
Sales Q/Q -
Earnings Mar 26 BMO
Avg Volume 24.53K
Price 3.10
SMA20 -15.76%
SMA50 -16.57%
SMA200 -46.26%
Trades
Volume 5,246
Change 6.22%
Apr-24-24 02:52PM
Mar-26-24 07:30AM
Feb-27-24 07:31AM
07:30AM
Feb-07-24 07:30AM
07:30AM
Loading…
Dec-29-23 07:30AM
Nov-17-23 07:10AM
07:00AM
Nov-15-23 04:15PM
Oct-31-23 08:58AM
Oct-12-23 08:02AM
Oct-02-23 08:58AM
Sep-27-23 08:58AM
Sep-26-23 08:58AM
Sep-22-23 11:27AM
(American City Business Journals)
10:00AM
Loading…
Sep-21-23 10:00AM
Sep-18-23 07:58AM
Sep-05-23 09:00AM
Aug-28-23 08:58AM
Aug-14-23 09:00AM
Aug-10-23 08:58AM
Jul-24-23 07:00AM
Jul-13-23 08:58AM
Jun-21-23 08:00AM
Jun-20-23 04:10PM
Jun-13-23 08:58AM
May-12-23 04:08PM
May-10-23 07:15AM
May-09-23 07:15AM
May-04-23 08:58AM
03:30PM
Loading…
May-02-23 03:30PM
Apr-27-23 08:58AM
Apr-05-23 08:58AM
Mar-28-23 08:58AM
Mar-22-23 08:58AM
Feb-13-23 08:58AM
Jan-31-23 08:58AM
Jan-18-23 09:00AM
Jan-10-23 09:00AM
Jan-04-23 09:00AM
Dec-14-22 09:00AM
Nov-09-22 09:00AM
Oct-13-22 06:29AM
Aug-24-22 09:00AM
Aug-15-22 09:00AM
Jul-22-22 11:32AM
(American City Business Journals)
Jul-05-22 09:00AM
Jul-01-22 04:04PM
06:33AM
(The Wall Street Journal)
Jun-30-22 06:44AM
04:00AM
Jun-29-22 04:06PM
(Yahoo Finance Video) +6.37%
11:30AM
09:32AM
Jun-28-22 07:08PM
05:01PM
(American City Business Journals)
04:37PM
(The Wall Street Journal)
11:14AM
Jun-27-22 12:13PM
(American City Business Journals)
09:00AM
Jun-24-22 12:25PM
Jun-23-22 04:34PM
(American City Business Journals)
04:00AM
May-19-22 09:00AM
May-16-22 09:00AM
May-06-22 06:12AM
May-05-22 09:00AM
Apr-26-22 09:00AM
Mar-31-22 09:00AM
Mar-22-22 09:00AM
04:00AM
Mar-15-22 01:45PM
10:06AM
(American City Business Journals)
09:00AM
Feb-15-22 09:00AM
Feb-10-22 09:00AM
Jan-21-22 11:00AM
Jan-18-22 09:00AM
Jan-04-22 09:20AM
Dec-28-21 08:00AM
Dec-20-21 08:00AM
Dec-08-21 08:00AM
Dec-01-21 07:16AM
Nov-27-21 08:04AM
Nov-15-21 08:00AM
Nov-10-21 08:00AM
Oct-20-21 07:00AM
Oct-06-21 09:00AM
Oct-01-21 08:00AM
Sep-20-21 09:00AM
Sep-16-21 01:00PM
Sep-14-21 02:49PM
12:27PM
10:11AM
09:05AM
Sep-13-21 07:07AM
Sep-02-21 09:00AM
Aug-26-21 02:51PM
09:00AM
Aug-19-21 07:07AM
Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company, which engages in the development of branded, non-addictive pain management products. Its products include metered-dose spray, liposomal gel encapsulates, and intranasal spray. The company was founded by Anthony P. Mack and Jeffrey A. Gudin in 2016 and and is headquartered in Berwyn, PA.
Index -
P/E -
EPS (ttm) -12.32
Insider Own 1.42%
Shs Outstand 5.47M
Perf Week -31.84%
Market Cap 7.49M
Forward P/E -
EPS next Y -
Insider Trans 6.88%
Shs Float 5.39M
Perf Month -45.20%
Income -48.93M
PEG -
EPS next Q -
Inst Own 13.65%
Short Float 1.19%
Perf Quarter -25.54%
Sales 0.00M
P/S -
EPS this Y -
Inst Trans -42.30%
Short Ratio 0.80
Perf Half Y -69.82%
Book/sh 1.16
P/B 1.18
EPS next Y -
ROA -123.92%
Short Interest 0.06M
Perf Year -89.93%
Cash/sh 2.70
P/C 0.51
EPS next 5Y -
ROE -171.26%
52W Range 1.22 - 20.66
Perf YTD -57.72%
Dividend Est. -
P/FCF -
EPS past 5Y 63.67%
ROI -663.50%
52W High -93.37%
Beta 1.73
Dividend TTM -
Quick Ratio 3.31
Sales past 5Y 0.00%
Gross Margin -
52W Low 12.30%
ATR (14) 0.25
Dividend Ex-Date -
Current Ratio 3.31
EPS Y/Y TTM -3.61%
Oper. Margin 0.00%
RSI (14) 30.23
Volatility 17.48% 11.23%
Employees 22
Debt/Eq 0.03
Sales Y/Y TTM -
Profit Margin -
Recom 3.00
Target Price 22.00
Option/Short No / Yes
LT Debt/Eq 0.01
EPS Q/Q 7.17%
Payout -
Rel Volume 0.50
Prev Close 1.29
Sales Surprise -
EPS Surprise -
Sales Q/Q -
Earnings -
Avg Volume 79.54K
Price 1.37
SMA20 -35.59%
SMA50 -40.21%
SMA200 -66.92%
Trades
Volume 39,627
Change 6.20%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-20-20 Resumed
ROTH Capital
Buy
$14
Apr-22-24 08:56AM
Apr-19-24 04:30PM
Apr-16-24 11:52PM
Mar-06-24 08:30AM
Feb-16-24 08:00AM
05:15PM
Loading…
Jan-03-24 05:15PM
Dec-07-23 08:00AM
Nov-28-23 04:15PM
Nov-13-23 04:05PM
Nov-10-23 08:50AM
Oct-25-23 08:30AM
Sep-29-23 08:00AM
Sep-21-23 04:05PM
08:00AM
Sep-19-23 09:00AM
11:01AM
Loading…
Sep-18-23 11:01AM
Sep-14-23 08:45AM
Sep-06-23 04:30PM
Jun-15-23 04:45PM
08:22AM
May-24-23 04:45PM
May-22-23 07:00AM
May-19-23 04:05PM
May-10-23 11:15AM
Apr-17-23 04:15PM
Mar-30-23 08:45AM
Mar-16-23 04:10PM
Mar-02-23 04:15PM
09:15AM
Feb-09-23 04:15PM
09:15AM
Loading…
Jan-18-23 09:15AM
Jan-10-23 04:15PM
Jan-09-23 08:00AM
Jan-05-23 04:15PM
Dec-05-22 04:30PM
09:00AM
Nov-07-22 08:00AM
Nov-04-22 08:30AM
Nov-02-22 08:00AM
Oct-26-22 08:00AM
Oct-20-22 04:30PM
Oct-19-22 08:00AM
Sep-26-22 05:00PM
Sep-14-22 08:00AM
Sep-12-22 08:00AM
Sep-08-22 08:00AM
Aug-31-22 08:00AM
Jul-22-22 04:15PM
Jul-04-22 10:23AM
Jun-28-22 08:30AM
Jun-24-22 04:15PM
Jun-20-22 08:00AM
Jun-15-22 08:00AM
Jun-14-22 08:00AM
May-31-22 04:30PM
May-27-22 08:54AM
08:00AM
May-03-22 08:00AM
Mar-07-22 08:00AM
Feb-15-22 08:00AM
Feb-14-22 08:00AM
Jan-26-22 08:00AM
Jan-12-22 08:00AM
Jan-06-22 04:15PM
Jan-05-22 04:30PM
08:30AM
Dec-21-21 08:00AM
Nov-30-21 08:00AM
Nov-16-21 08:45AM
Nov-10-21 08:00AM
07:55AM
Nov-04-21 08:00AM
Nov-02-21 08:00AM
Oct-07-21 08:00AM
Sep-29-21 09:00AM
Sep-13-21 08:00AM
Sep-10-21 04:05PM
Aug-15-21 05:50AM
Jul-23-21 04:40PM
Jul-13-21 08:00AM
Jun-25-21 04:30PM
Jun-09-21 07:45AM
May-16-21 05:10AM
May-06-21 07:45AM
Apr-29-21 09:50AM
Mar-23-21 07:15AM
Mar-22-21 04:30PM
Mar-11-21 07:30AM
Feb-18-21 04:30PM
Feb-16-21 06:45AM
Feb-12-21 04:45PM
Feb-10-21 07:30AM
Feb-09-21 04:30PM
Feb-05-21 02:00AM
Jan-29-21 03:07PM
Jan-05-21 08:00AM
Dec-29-20 04:15PM
07:30AM
Dec-22-20 07:30AM
Dec-10-20 08:55AM
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. It focuses on the development of its product candidate rencofilstat, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Wijngaard Peter Director Nov 27 '23 Buy 3.05 2,500 7,625 9,501 Nov 28 06:55 AM Wijngaard Peter Director Nov 24 '23 Buy 3.09 2,500 7,725 7,001 Nov 28 06:55 AM Wijngaard Peter Director Sep 19 '23 Buy 5.64 1,000 5,640 4,501 Sep 20 11:27 AM Foster Robert T CEO and Director Sep 18 '23 Buy 5.60 1,600 8,960 50,470 Sep 19 09:01 AM Wijngaard Peter Director Sep 15 '23 Buy 5.60 2,000 11,201 3,501 Sep 20 11:27 AM Foster Robert T CEO,CSO and Director Sep 15 '23 Buy 5.40 1,600 8,640 48,870 Sep 18 08:00 AM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite